Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Conditions
Brief summary
This is a prospective, multicenter, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for patients with relapsed/refractory large granular T lymphocytic leukemia.
Interventions
DRUGLinperlisib
Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Sponsors
YL-Pharma
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female age ≥ 18 years * Diagnosis of T-cell large granular lymphocytic leukemia (T-LGLL) * Meet any of the following indications for treatment： 1. Hemoglobin \< 100g/L or RBC transfusion dependence 2. Neutrophil count \<0.5×10\^9/L or neutrophil count decreased with recurrent infection 3. Progressive splenomegaly and/or Massive Splenomegaly 4. Combined with autoimmune diseases requiring treatment, such as rheumatoid arthritis, autoimmune thyroiditis, etc. 5. Severe B symptoms * Failure or intolerance to a first-line therapy * ECOG performance status ≤2 * Expected survival ≥ 6 months * Willing and able to comply with the requirements for this study and written informed consent
Exclusion criteria
* History of other lymphoproliferative neoplasms * Had malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors * Previously received organ or stem cell transplantation * Patients with active infection within 2 weeks before giving the first dose of medication * Patients with HBV, HCV, HIV or other infections that require treatment * History of immunodeficiency, or congenital immunodeficiency disorders * Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, metabolic disorders and other diseases that seriously affect the function of the gastrointestinal tract. * Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values * Renal impairment: creatinine clearance \<30ml/min * History of mental illness * History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of lung function, etc. * Received attenuated vaccine 4 in weeks before enrollment * Participation in another clinical trial within 4 weeks before the start of this trial * Have an allergy to Linperlisib or any other part of this medicine. * Pregnant or breast-feeding patients * Patients considered to be ineligible for the study by the investigator for reasons other than the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with hematologic remission | 8-12 weeks | Hematological response is evaluated by hemoglobin (Hb), absolute neutrophil count (ANC), platelet count (PLT), absolute lymphocyte count (ALC), absolute large granular lymphocyte count, and blood transfusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of the adverse event | 8-12 weeks | Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event |
Countries
China
Contacts
Primary ContactJun Shi, PhD
Backup ContactLele Zhang, PhD
Outcome results
None listed